Litfulo (ritlecitinib) / Pfizer - LARVOL DELTA

Disseminated maculopapular drug eruption caused by ritlecitinib in a patient with alopecia areata. (PubMed, Eur J Dermatol) - No abstract available

Journal • Alopecia • Immunology

Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery. (PubMed, J Am Chem Soc) - "Since the synthetic methodology is established in advance of fragment screening and utilizes robust chemistry, the elaboration of fragment hits in 3-D for biochemical screening can be achieved rapidly. To provide proof-of-concept, starting from the drug Ritlecitinib, the development of inhibitors of Janus kinase 3 (JAK3) around a putative pyrrolopyrimidine 2-D fragment hit was explored, streamlining the discovery of a novel and selective JAK3 inhibitor with IC50 = 69 nM."

Journal • JAK3

Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study. (PubMed, J Dermatol) - "Notably, five new and unexpected significant AEs that were off-label were also found, including diabetes mellitus, hair color changes, thyroid disorder, blood cholesterol abnormality, and increased lipids. Our study could provide a comprehensive safety overview of ritlecitinib during patient treatment and guide its clinical practice."

Adverse events • Journal • Real-world evidence • Acne Vulgaris • Alopecia • Dermatology • Diabetes • Endocrine Disorders • Immunology • Infectious Disease • Metabolic Disorders • Pain • Urticaria

Effectiveness and safety of baricitinib and ritlecitinib in the treatment of alopecia areata: A 6-Month descriptive outcome analysis from a spanish tertiary hospital (EADV 2025) - No abstract available

Clinical • Alopecia • Immunology

Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Ahuva D Cices | Initiation date: Feb 2025 ➔ Sep 2025

Trial initiation date • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Phase 3 Findings on Long-Term Ritlecitinib in Adults, Adolescents with Alopecia Areata (HCPLive) - P3 | N=1,052 | ALLEGRO-LT (NCT04006457) | Sponsor: Pfizer | "The data was presented as a poster at the Dermatology Education Foundation (DERM) 2025 NP/PA CME Conference....By 24 months, 73.5% and 66.4% of those involved attained SALT scores ≤20 and ≤10, respectively. Overall, Senna and coauthors concluded that ritlecitinib 50 mg treatment among patients with alopecia areata demonstrated meaningful clinician- and patient-reported efficacy. 86.1% of those assessed in ALLEGRO-LT were found to have reported treatment-emergent adverse events (AEs), although most were noted by the investigators as being mild or moderate in severity. They concluded that the most frequent AEs were positive SARS-CoV-2 test in 24.2%, headaches in 20.8%, and pyrexia in 13.0%. Rates of serious AEs, severe AEs, and discontinuations of ritlecitinib were shown by Senna and colleagues to be 4.9%, 6.0% and 6.5%, respectively."

P3 data • Alopecia

Real world' use of ritlecitinib for alopecia areata in its first 12-months of approval in the United Kingdom (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Prediction of long-term scalp hair regrowth at 24 months in patients with alopecia areata receiving ritlecitinib treatment in the ALLEGRO clinical trial program (EADV 2025) - No abstract available

Clinical • Alopecia • Immunology

Real-world Evaluation of Ritlecitinib for Severe Alopecia Areata: Insights from a Teaching Hospital in the UK (EADV 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Alopecia • Immunology

Pediatric clinical trial program in progress: A phase 3 study and long-term extension study to evaluate the efficacy and safety of ritlecitinib in children 6 to <12 years of age with severe alopecia areata (EADV 2025) - No abstract available

Clinical • P3 data • Alopecia • Immunology • Pediatrics

Updated integrated safety analysis of ritlecitinib over 72 months in patients with alopecia areata (AA) from the ALLEGRO clinical trial program (EADV 2025) - No abstract available

Clinical • Alopecia • Immunology

Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (EADV 2025) - No abstract available

Retrospective data • Review • Alopecia • Immunology

Real-world Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Ritlecitinib for the treatment of severe alopecia areata: real-world experience from a tertiary centre (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Unraveling the underlying mechanism of ritlecitinib's therapeutic actions in alopecia areata (EADV 2025) - No abstract available

Alopecia • Immunology

Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy. (PubMed, Allergy) - P2a | "These results provide support that treatment with ritlecitinib improves the gene expression profile in AA lesional scalp and is correlated with subsequent hair regrowth response."

Journal • Alopecia • Immunology • CCL18 • CD8 • GZMB • JAK3

Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors. (PubMed, J Am Acad Dermatol) - "Prior JAK inhibitor exposure as a significant factor influencing early treatment response. Responses of lashes, brows and nails were similar to scalp."

Journal • Real-world evidence • Alopecia • Immunology

Ritlecitinib in CTCL (clinicaltrials.gov) - P2 | N=7 | Terminated | Sponsor: Icahn School of Medicine at Mount Sinai | Active, not recruiting ➔ Terminated | Trial primary completion date: Jan 2025 ➔ Jun 2025; No significant improvement in disease as graded by our assessments.

Trial primary completion date • Trial termination • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Successful repigmentation with ritlecitinib and combined home-based phototherapy in an intractable case of generalized vitiligo. (PubMed, An Bras Dermatol) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Real-world assessment of ritlecitinib in patients with severe alopecia areata: A 24-week multicenter retrospective study. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Real-world evidence • Retrospective data • Alopecia • Immunology

LINKING SERUM BIOMARKERS TO HISTOLOGICAL EVIDENCE OF INFLAMMATION IN IBD: A PILOT STUDY ON EXTRACELLULAR MATRIX AND NEUTROPHIL ACTIVATION FOLLOWING RITLECITINIB TREATMENT (UEGW 2025) - No abstract available

Biomarker • Clinical • Inflammation • Inflammatory Bowel Disease

Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata. (PubMed, J Cosmet Dermatol) - "We present a case report documenting secondary failure of tofacitinib in the treatment of AA. This case highlights potential insights into the pathogenesis of AA and may inform the development of future therapeutic strategies."

Journal • Alopecia • Immunology

JAK/STAT signalling pathway is involved in the immune mechanism of Bullous pemphigoid. (PubMed, Br J Dermatol) - "JAK3 inhibitors can attenuate JAK3/STAT3-mediated inflammatory factors, providing an alternative treatment strategy for refractory BP patients in combination with low-dose steroids."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • CCL18 • CCL2 • CCL22 • GZMB • IL5 • JAK1 • JAK3 • MMP9 • STAT3

Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary. (PubMed, Immunotherapy) - No abstract available

Journal

A Response to: Letter to the Editor Regarding "Efficacy and Safety of Zimlovisertib, Ritlecitinib and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate". (PubMed, Arthritis Rheumatol) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology